Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Heldmann

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Arthritis and Rheumatism|May 13, 2010
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trialI-H Song, F Heldmann, M Rudwaleit, et al.
Zeitschrift Fur Rheumatologie|October 2, 2019
[Future of rheumatologists: what are the perspectives? : Survey of resident physicians in rheumatology in middle Germany]A Pfeil, C G O Baerwald, M Sieburg, et al.
RMD Open|August 6, 2016
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reductionX Baraliakos, F Heldmann, F van den Bosch, et al.
Clinical and Experimental Rheumatology|September 13, 2011
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximabF Heldmann, J Brandt, I E van der Horst-Bruinsma, et al.
Zeitschrift Fur Rheumatologie|December 19, 2015
[Do we still need clinical studies in rheumatology?]U Henkemeier, R Alten, B Bannert, et al.
Annals of the Rheumatic Diseases|July 16, 2013
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiographyX Baraliakos, F Heldmann, J Callhoff, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Arthritis and Rheumatism|May 13, 2010
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trialI-H Song, F Heldmann, M Rudwaleit, et al.
Zeitschrift Fur Rheumatologie|October 2, 2019
[Future of rheumatologists: what are the perspectives? : Survey of resident physicians in rheumatology in middle Germany]A Pfeil, C G O Baerwald, M Sieburg, et al.
RMD Open|August 6, 2016
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reductionX Baraliakos, F Heldmann, F van den Bosch, et al.
Clinical and Experimental Rheumatology|September 13, 2011
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximabF Heldmann, J Brandt, I E van der Horst-Bruinsma, et al.
Zeitschrift Fur Rheumatologie|December 19, 2015
[Do we still need clinical studies in rheumatology?]U Henkemeier, R Alten, B Bannert, et al.
Annals of the Rheumatic Diseases|July 16, 2013
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiographyX Baraliakos, F Heldmann, J Callhoff, et al.
Pageof 2